New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 26, 2012
12:22 EDTNIHD, SWI, AKAM, REGN, CTXS, UPS, LEAP, PCS, AET, XLNX, CHK, XOM, BCO, ALU, PHM, EQIX, JNJOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, in spite of jobless claims that were higher than expected and disappointing results from Exxon Mobil (XOM). Stocks began the day quietly following the jobless claims data. The averages were mixed in the opening half hour but spurted higher following the March pending home sales report. The data was much better than expected and pushed the averages to their session highs. The averages have since remained in a narrow range but have drifted higher... ECONOMIC EVENTS: Domestically, 388,000 initial jobless claims were reported, versus expectations of 375,000. Continuing claims came in at 3.31M, versus expectations for 3.29M. The Chicago Fed National Activity Index had a reading of -0.29. Pending home sales for the month of March were up 4.1% from the prior month, versus expectations of an increase of 1.0%... COMPANY NEWS: Exxon Mobil and UPS (UPS) both reported revenues and earnings that missed expectations, sending shares of both tumbling. Exxon slid almost 2% following its report, while UPS fell over 3%... Johnson & Johnson (JNJ) increased its dividend by 7%... Reuters reported that the SEC opened an informal inquiry into Chesapeake Energy's (CHK) well participation program as the company came out separately and said it did not review or approve of specific transactions made by its CEO Aubrey McClendon under that program... Among companies reporting earnings, advancers included Citrix Systems (CTXS), Equinix (EQIX), Xilinx (XLNX), Regeneron (REGN) and Pulte (PHM); decliners included Aetna (AET), Akamai (AKAM), Alcatel-Lucent (ALU) and MetroPCS (PCS)... MAJOR MOVERS: Among the notable gainers were SolarWinds (SWI), up 19%, after guiding to FY12 adjusted earnings that were above consensus at the midpoint, and Brinks (BCO), up over 17%, following results that beat on both the top and bottom line. Noteworthy losers included Leap Wireless (LEAP), down 20%, following downgrades at Raymond James and Guggenheim after its weak Q1 results, and NII Holdings (NIHD), down more than 18%, after its revenues and earnings disappointed... INDICES: Near noon, the Dow was up 63.46, or 0.48%, to 13,154.18; the Nasdaq was up 6.61, or 0.22%, to 3,036.24; and the S&P 500 was up 2.62, or 0.19%, to 1,393.31.
News For XOM;UPS;JNJ;CHK;CTXS;EQIX;XLNX;REGN;PHM;AET;AKAM;ALU;PCS;SWI;BCO;LEAP;NIHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 10, 2014
14:45 EDTAETDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
09:35 EDTCTXSCitrix management to meet with William Blair
Subscribe for More Information
08:14 EDTUPSUPS management to meet with UBS
Meeting to be held in Seoul, South Korea on December 10 hosted by UBS.
08:04 EDTXOMExxon Mobil management to meet with UBS
Subscribe for More Information
07:26 EDTPHMPulteGroup price target raised to $26 from $23 at Susquehanna
Susquehanna raised its price target on PulteGroup to reflect the company's current return profile, which has done better than its historic average. Susquehanna reiterated its Positive rating on PulteGroup shares.
07:24 EDTBCOImperial Capital to hold a conference
Subscribe for More Information
December 9, 2014
14:22 EDTAETAetna updates clinical policy for H.P. Acthar Gel
Subscribe for More Information
08:55 EDTXOMExxon Mobil to hold a webcast
Vice Presidents Colton and Cohen hold a webcast to launch ExxonMobil's 2015 Outlook for Energy: A View to 2040 on December 9 at 1 pm. Webcast Link
07:46 EDTUPSUPS management to meet with UBS
Subscribe for More Information
07:41 EDTCTXSBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 9 at 10:40 am; not all company presentations may be webcasted. Webcast Link
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
14:30 EDTPHMPulteGroup December volatility elevated into investor day
Subscribe for More Information
12:38 EDTAKAMAkamai management to meet with Pacific Crest
Subscribe for More Information
08:11 EDTUPSUPS management to meet with UBS
Subscribe for More Information
08:09 EDTXOMExxon Mobil management to meet with UBS
Subscribe for More Information
07:53 EDTXOMClimate for Exxon E&P acquisition improved by falling prices, WSJ says
Subscribe for More Information
07:28 EDTEQIX, AKAMFBN Securities to hold a bus tour
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use